Sign in

CIK 0001689375

  • Accelerated filer
  • Smaller reporting company
  • Emerging growth company

Entrada Therapeutics, Inc.

Sign in to watch
Ticker
TRDA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813983399
Phone
+1 857-305-1825
Business address
ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
Former names
CycloPorters, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$7,200,939
in 8 filings

Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 21 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-09-06 KREHER NERISSA Chief Medical Officer Sale 10b5-1 −21 $14.00 $294 40,037
2023-09-06 Dowden Nathan J Chief Operating Officer Sale 10b5-1 −913 $13.43 $12K 48,227
2023-09-06 Dowden Nathan J Chief Operating Officer Sale 10b5-1 −59 $14.01 $826 48,168
2023-09-05 Doshi Dipal President and CEO Shares withheld for taxes −1,440 $14.46 $21K 249,279
2023-09-05 WENTWORTH KORY JAMES Chief Financial Officer Shares withheld for taxes 10b5-1 −426 $14.46 $6K 50,521
2023-09-05 Sethuraman Natarajan Chief Scientific Officer Shares withheld for taxes −449 $14.46 $6K 167,198
2023-09-05 KREHER NERISSA Chief Medical Officer Shares withheld for taxes 10b5-1 −401 $14.46 $6K 40,929
2023-09-05 Dowden Nathan J Chief Operating Officer Shares withheld for taxes 10b5-1 −436 $14.46 $6K 49,140
2023-09-01 Doshi Dipal President and CEO Grant or award +49,650 250,719
2023-09-01 Doshi Dipal President and CEO Grant or award · Stock Option (Right to Buy) +75,250 75,250
2023-09-01 WENTWORTH KORY JAMES Chief Financial Officer Grant or award 10b5-1 +14,200 50,947
2023-09-01 WENTWORTH KORY JAMES Chief Financial Officer Grant or award · Stock Option (Right to Buy) 10b5-1 +21,500 21,500
2023-09-01 Sethuraman Natarajan Chief Scientific Officer Grant or award +14,200 167,647
2023-09-01 Sethuraman Natarajan Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +21,500 21,500
2023-09-01 KREHER NERISSA Chief Medical Officer Grant or award 10b5-1 +14,200 41,330
2023-09-01 KREHER NERISSA Chief Medical Officer Grant or award · Stock Option (Right to Buy) 10b5-1 +21,500 21,500
2023-09-01 Dowden Nathan J Chief Operating Officer Grant or award 10b5-1 +14,200 49,576
2023-09-01 Dowden Nathan J Chief Operating Officer Grant or award · Stock Option (Right to Buy) 10b5-1 +21,500 21,500
2023-09-01 Chapman Gina Director Grant or award · Stock Option (Right to Buy) +32,000 32,000
2023-08-14 Doshi Dipal President and CEO Sale 10b5-1 −1,000 $15.67 $16K 201,069

Page 14 of 26 · 517 trades